Monday 11 Aug, 2025 03:23 PM
Site map | Locate Us | Login
   Dr Reddy's Lab receives EIR from USFDA for Telangana API facility    Sharika Enterprises Ltd leads losers in 'B' group    Barometers trade higher; auto shares climb    Ipca Labs Q1 PAT climbs 21% YoY to Rs 233 cr    Volumes spurt at Doms Industries Ltd counter    L&T edges higher after bagging 'ultra-mega' thermal power project from Adani Power    Ceigall India slips after Q1 PAT slides 33% YoY to Rs 53 cr    Shipping Corp Q1 PAT jumps 21% YoY to Rs 354 cr    Mankind Pharma Ltd slips for fifth straight session    NLC India Ltd down for fifth straight session    Samvardhana Motherson International Ltd down for fifth straight session    NSE SME Bhadora Industries starts with a faint current on listing day    Suprajit Engg slides after Q1 PAT drop 3% YoY to Rs 49 cr    NSE SME Parth Electricals & Engineering sparks gain on market debut    Dr Reddys Laboratories Ltd soars 1.07% 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
Lupin gains after launching Glucagon for Injection in U.S. market
11-Aug-25   11:04 Hrs IST

The product is bioequivalent to Eli Lilly and company's Glucagon for Injection, 1 mg/vial, and is used in the treatment of severe hypoglycaemia in paediatric and adult patients with diabetes mellitus. It is also indicated as a diagnostic aid during radiologic examinations to temporarily inhibit gastrointestinal motility in adult patients.

According to IQVIA MAT (June 2025) data, Glucagon for Injection USP, 1 mg/vial packaged in an emergency kit, had estimated annual sales of $122 million in the U.S. market.

Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.

Lupin's consolidated net profit jumped 52.13% to Rs 1,219.03 crore on 11.78% increase in income from operations to Rs 6,163.75 crore in Q1 FY26 over Q1 FY25.

Powered by Capital Market - Live News
   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.R Udayakumar , compliance@ssplwealth.com,  Mobile No: 7305522205
Investor Charter | Annual Return | Account Closure | RE-KYC | Disclaimer | Feed Back | Privacy Policy | Policies & Procedures | Rights & Obligations-English | (Rights & Obligations, Risk Disclosure Document, Do's & Don't's) in Vernacular Language | Anti Money Laundering Policy | E-Voting | CSR | Voluntary Freezing / Blocking | Policy GTC | Policy On Inactive Trading Accounts | Risk Disclosure Hit Count : 43374680
Useful Links : NSE | BSE | MCX | NSDL | CDSL | SEBI | RBI | ATTENTION INVESTOR| SMART ODR
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 56990 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. SSPL Securities Private Limited